Paper Details

  1. Home
  2. Paper Details

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Author: BarthRichard J, ColeBernard F, CrocenziTodd S, CrosbyNancy A, ErnstoffMarc S, FisherJan L, FosterCathy, HarrisRobert D, HeaneyJohn A, MellingerDiane, NoelleRandolph J, SchnedAlan R, SchwaabThomas, SchwarzerAdrian, SeigneJohn D, SzczepiorkowskiZbigniew M, UhlenhakeJill C, WebberSusan M, WolfBenita

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A DC vaccine with IL-2 and IFN-alpha 2a showed a 50% objective clinical response rate in metastatic renal cell carcinoma patients, including three complete responses. Further exploration of this approach is warranted.
Paper Details　
Original Abstract of the Article :
PURPOSE: To evaluate the clinical and immunologic outcomes of DC (dendritic cell) vaccine with interleukin (IL)-2 and IFN-alpha 2a in metastatic renal cell carcinoma patients. EXPERIMENTAL DESIGN: Eighteen consented and eligible patients were treated. Peripheral blood monocytes were cultured ex viv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/19622576

データ提供：米国国立医学図書館（NLM）

A Promising Combination Therapy for Metastatic Renal Cell Carcinoma

This study takes us into the world of cancer immunotherapy, exploring the effectiveness of a novel treatment strategy for metastatic renal cell carcinoma (RCC). Researchers investigated the clinical and immunologic outcomes of a combination therapy involving dendritic cell (DC) vaccination with interleukin (IL)-2 and IFN-alpha 2a in patients with metastatic RCC. They aimed to understand the potential benefits and mechanisms of this treatment approach.

A Combination Therapy Showing Promise

The study found that the combination therapy showed promising results in patients with metastatic RCC, with a significant objective response rate, including complete responses. Furthermore, the treatment induced changes in immune parameters, suggesting a potential for stimulating anti-tumor immune responses. These findings highlight the potential of this combination therapy for improving patient outcomes in metastatic RCC.

A New Hope for Cancer Treatment

This study offers a glimmer of hope for patients with metastatic RCC. It showcases the potential of immunotherapy, specifically DC vaccination combined with cytokine therapy, for treating this challenging disease. Just as a desert traveler seeks a source of water to sustain life, cancer patients search for effective treatments to combat their disease. This study suggests that combination immunotherapy could offer a lifeline for patients with metastatic RCC.

Dr.Camel's Conclusion

This research highlights the promising potential of combination immunotherapy, specifically DC vaccination with IL-2 and IFN-alpha 2a, for treating metastatic RCC. It's a reminder that research continues to advance, offering new hope for cancer patients. Just as a desert oasis provides a refreshing respite from the harsh conditions, immunotherapy offers a glimmer of hope for those battling this challenging disease.

Date :
  1. Date Completed 2009-11-30
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

19622576

DOI: Digital Object Identifier

NIHMS511033

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.